Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: June 2012
-
BIO and the America Invents Act By Andrew Williams — The 2012 BIO International Convention begins in Boston next week. Patent Docs has been highlighting a few sessions, in thematic fashion, to help you navigate your way through the convention. Today, in this final installment, we review a few opportunities for those interested in learning…
-
By Kevin E. Noonan — The Federal Circuit today denied Defendant Myriad Genetics' motion, styled as "Appellant's Suggestion of Mootness, or, in the Alternative, Motion to Remand," seeking to reopen the question of whether Dr. Harry Ostrer continues to have standing to bring the lawsuit (see "Myriad Files Motion 'Suggesting' Mootness or Seeking Remand in…
-
BIO and Biosimilar Regulations throughout the World By Andrew Williams — The 2012 BIO International Convention in Boston begins next week. If you are planning on attending, Patent Docs is highlighting a few sessions, in thematic fashion, to help navigate your way through the Convention. Last week, we highlighted three sessions on how the Supreme…
-
By Donald Zuhn — Last week, we reported on the release of the Intellectual Property Owners Association's (IPO) list of the Top 300 organizations receiving U.S. patents in 2011 (see "IPO Releases List of Top 300 Patent Holders for 2011"). As in past years, Patent Docs used the IPO's list of top patent holders to…
-
By Kevin E. Noonan — On May 30th, Myriad Genetics filed a motion in the remand of Association for Molecular Pathology v. U.S. Patent and Trademark Office case ("Myriad") to the Federal Circuit, styled "Appellant's Suggestion of Mootness, or, in the alternative, Motion to Remand," to address the fundamental question of whether the Federal Circuit,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Fidopharm Inc. v. Merial Ltd.1:12-cv-00714; filed June 5, 2012 in the District Court of Delaware Declaratory judgment of non-infringement and invalidity of U.S. Patent No. 6,096,329 ("Insecticidal Combination to Control Mammal Fleas, in Particular Fleas…
-
June 13-15, 2012 – Fundamentals of Patent Prosecution 2012: A Boot Camp for Claim Drafting & Amendment Writing (Practising Law Institute) – New York, NY June 14, 2012 – The Elimination and Creation of Defenses in the Wake of AIA (Technology Transfer Tactics) – 1:00 – 2:00 pm (Eastern) June 18-21, 2012 – BIO International…
-
Strafford will be offering a webinar/teleconference entitled "Inducement to Infringe in Hatch-Waxman Litigation: Lessons from Bayer Schering v. Lupin and AstraZeneca v. Apotex for Pharma Patents" on July 12, 2012 from 1:00 – 2:30 pm (EDT). Thomas L. Irving and David P. Frazier, Ph.D. of Finnegan Henderson Farabow Garrett & Dunner will provide guidance on…
-
Life Sciences Top 50 (plus 3) By Donald Zuhn — On Wednesday, the Intellectual Property Owners Association (IPO) released its 29th annual list of the top 300 organizations receiving U.S. patents. Patent Docs Readers may recall that the U.S. Patent and Trademark Office stopped releasing its annual list of top patent recipients in 2006 in…
-
By Kevin E. Noonan — Hans Sauer, Associate General Counsel for Intellectual Property for the Biotechnology Industry Organization (BIO), frequently asks (when discussing patent-eligibility of genes): "What about cucumber genes? Should they be patented?" If Hans wishes to remain au courant, however, he will need to update this question by asking "What about tomato genes?"…
Patent Docs 